Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Cizzle Biotech (CIZ) Share News

TRADING UPDATES: Fiinu teams with TransUnion; GRC wins pact

23rd Dec 2022 18:15

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: Cizzle Biotechnology signs lung-cancer study in China

23rd Nov 2022 16:58

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Signs further Memorandum of Understanding with International Co-Innovation Centre for Advanced Medical Technology for a clinical pilot study with the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Center of China. The clinical pilot study will evaluate optimised assays using a monoclonal antibody that Cizzle Biotechnology has developed that specifically detects CIZ1B, which is highly associated with stage 1 lung cancer. Read More

UPDATE: Cizzle, Vela Technologies notes planned Conduit Pharma merger

9th Nov 2022 20:41

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - and Vela Technologies PLC - Bradford, England-based investment firm focused on early-stage and pre-IPO disruptive technology investments - Notes announcement by Conduit Pharmaceuticals Ltd that it intends to become a publicly traded company on the Nasdaq in the US through a merger with special purpose acquisition firm Murphy Cannon Acquisition Corp. The deal is expected to generate USD149.7 million worth of proceeds for Conduit. Read More

Cizzle Biotechnology reports narrowed loss as passes "key milestones"

28th Sep 2022 14:43

(Alliance News) - Cizzle Biotechnology Holdings PLC on Wednesday said it had passed "key milestones" as it moved towards generating revenue for its products. Read More

Vela Tech, Cizzle Biotech shares jump on investee's trial results

18th Aug 2022 11:37

(Alliance News) - Vela Technologies PLC and Cizzle Biotechnology Holdings PLC on Thursday hailed the latest clinical trial results from investee St George Street Capital Ltd. Read More

Cizzle Biotechnology expands use of lung cancer test

5th Jul 2022 12:15

(Alliance News) - Cizzle Biotechnology Holdings PLC on Tuesday said that it is using its early-stage lung cancer test technology to detect more cancer types, notably breast cancer. Read More

UK shareholder meetings calendar - next 7 days

20th Jun 2022 15:40

TRADING UPDATES: Valereum opens NFT market; Conygar considers raising

16th Jun 2022 16:55

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Cizzle Biotechnology widens annual loss on acquisition costs

30th May 2022 12:32

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Posts higher annual loss in 2021. Pretax loss widens to GBP4.0 million from GBP14,000 in 2020. In May 2021, Cizzle was bought by Bould Opportunities PLC. Acquisition-related costs stand at GBP3.1 million in 2021 versus none in 2020. Read More

AIM WINNERS & LOSERS: SDI upbeat; Westminster rises on contract win

6th May 2022 11:18

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More

Cizzle Biotechnology shares jump on US lung cancer collaboration

6th May 2022 10:11

(Alliance News) - Cizzle Biotechnology Holdings PLC on Friday announced a new collaboration into lung cancer testing with a US partner. Read More

TRADING UPDATES: WANdisco bookings up; STM legal appeal denied

11th Apr 2022 21:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: Cizzle Biotech notes promising data from Arcadia study

8th Mar 2022 06:45

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Reports that Arcadia clinical study shows potential value of AZD1656 treatment for Covid-19 patients. The new data analysis comes from St George Street Capital Ltd, which runs the trial with Excalibur Medicines Ltd for the treatment, in which Cizzle holds a "significant" royalty-bearing economic interest. Read More

FTSE 100 Latest

Value8,809.74

Change53.53